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length polymorphism analysis.  Results: In the index patient, 
we identified a homozygous TT genotype in exon 8 of the 
 EVER2/TMC8 gene (c.917A  ]  T, p.N306I). The same mutation 
could thereafter be detected in her sister from paraffin-em-
bedded skin.  Conclusion: We have followed one of the first 
patients described with EV in Basel, Switzerland, in 1930 un-
til today and demonstrated the TT genotype (SNP rs7208422) 
in the  EVER2/TMC8  gene in this index patient and her sister. 
The results underline the possible relevance of SNP rs7208422 
by influencing the susceptibility to   -papillomaviruses and 
their oncogenic potential.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Epidermodysplasia verruciformis Lewandowsky-Lutz 
(EV) is a rare genodermatosis characterised by develop-
ment of verruciform skin lesions caused by specific geno-
types of human papillomaviruses (HPV) of the   -papil-
lomavirus (  -HPV) genus  [1] . Patients are at high risk of 
developing carcinoma in situ and spinocellular carcino-
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 Abstract 
 Background: Epidermodysplasia verruciformis Lewandow-
sky-Lutz (EV) is a rare genodermatosis, characterised by de-
velopment of numerous verrucous skin lesions caused by 
specific genotypes of human papillomaviruses belonging to 
the   -papillomavirus genus. The EV loci were mapped to 
chromosome 2p21–p24 (EV2) and 17q25 (EV1). On chromo-
some 17, 2 adjacent related genes –  EVER1/TMC6  and  EVER2/
TMC8 – were identified. We reinvestigated 2 patients origi-
nally described by Wilhelm Lutz in 1946 with the aim to doc-
ument the natural course of the disease and confirm his di-
agnosis.  Methods: PCR fragments specific for exons with 
short flanking intron sequences of  EVER1/TMC6 and  EVER2/
TMC8 genes from patients’ DNA were amplified using se-
quence information. The single-nucleotide polymorphism 
(SNP) rs7208422 was studied, using restriction fragment 
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ma in UV light-exposed areas. At least 19   -HPV geno-
types have been found in EV patients. HPV type 5 is usu-
ally, and type 8 occasionally, cited with malignant con-
version  [2] . About 70% of patients with cancers have 
antibodies to HPV-5 oncoproteins E6 or E7 (early protein 
6 or 7)  [2] . The molecular mechanism of the E6 and E7 
proteins in causing skin cancer is not well understood. 
The viral E6 protein effectively blocks the epidermal 
apoptotic response to UV light and seems to play a role in 
promoting tumour development in cooperation with the 
mutagenic effects of UV  [3] . Mutations of the p53 gene in 
EV patients by UV light and an abnormal expression of 
the p53 protein have been found to be associated with tu-
mour progression. Therefore a syncarcinogenic effect of 
UV and   -HPV has been postulated. The finding that 
10% of patients have consanguineous parents and 10% of 
EV families have more than 1 descendant affected sug-
gests a genetic background may play a role. In general,
EV shows an autosomal recessive pattern of inheritance 
(OMIM 226400)  [4] . The EV loci were mapped to chro-
mosome 2p21–p24 (EV2) and 17q25 (EV1)  [5] , respective-
ly. In the EV1 interval, 2 adjacent related genes,  EVER1 
 and  EVER2, were identified in 2002  [6] . EVER proteins 
are members of the transmembrane channel-like (TMC) 
family. They are encoded by 8 genes (TMC1–8)  [7, 8] . 
 EVER1  and  EVER2 correspond to  TMC6  and  TMC8,  re-
spectively. They are involved in the intracellular zinc me-
tabolism  [9, 10] .
 Patients and Methods 
 EV was first described in Basel in 1922 by the dermatologists 
Felix Lewandowsky and Wilhelm Lutz ( fig. 1 )  [11] . They described 
a 29-year-old woman with 2 spinocellular carcinomas on her 
front and multiple reddish squamous papules, which resembled 
plane warts. Therefore, the authors called this disease ‘epidermo-
dysplasia verruciformis’. A second patient with EV originating 
from Basel was seen in the same year by the dermatologist Hein-
rich Fuchs  [12] .
 In 1946, Wilhelm Lutz published on 2 sisters which he had 
seen in 1929 and 1930 with the same disease  [13] . The older of 
them (named K.T.), born in 1912, showed verruca plana-like le-
sions on her neck, face and dorsal hands  [14] ( fig. 2 ). After 1947 
she developed several actinic keratoses and spinocellular carcino-
mas ( fig. 3 ). She died in 1983 after operation, and radiation, meth-
otrexate and bleomycin therapy of several spinocellular carcino-
mas with metastases in regional lymph nodes  [14]  ( fig. 4 ). A delay 
a b
 Fig. 1.  a Wilhelm Lutz.  b Felix Lewandowsky.  Fig. 2. Patient K.T. in 1929 with verrucous macules on the face and 
neck. Photograph by Wilhelm Lutz. 
 Fig. 3. Patient K.T. with spinocellular carcinoma of the nose and 
multiple actinic keratoses in 1976. 
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 Fig. 6. Typical verrucous lesions of index patient L.H. in 1936. 
Photograph by Wilhelm Lutz. 
G G GGA A A AC C C C C C CT TTTT
40
 Fig. 4. Patient K.T. in 1982, shortly before she died.  Fig. 5. Face of the index patient L.H. in 2009. 
 Fig. 7. Typical verruca plana-like lesions on the lower legs of index 
patient L.H. in 1982. 
 Fig. 8. Actinic keratosis and morbus Bowen in index patient L.H. 
in 1982. 
 Fig. 10. Homozygous missense mutation in exon 8 of  TMC8 
(c.917A  ]  T) of patient K.T. leading to an amino acid exchange 
(p.N306I). 
 Fig. 9. Hand of index patient L.H. almost free of lesions in 2009. 
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in therapy of several years after the first diagnosis of spinocellular 
carcinoma in 1957 was caused by applying Iscador therapy in ac-
cordance with the wish of the patient.
 The sister of K.T. (named L.H.), born in 1923, is still regularly 
controlled every 6 weeks in our clinic and the course is favourable 
( fig. 5 ). Since early childhood she has suffered from erythematous 
macules with a slight scaly appearance, mainly on her neck and 
hands ( fig. 6 )  [13] . The parents of the 2 sisters were not consan-
guineous. L.H. has 1 healthy daughter, K.T. had no children. In 
1946, Wilhelm Lutz published on the successful autoinoculation 
of the verruciform lesions in our patient L.H. and postulated that 
EV is not only a genetic abnormality  [13] . Jablonska and Milewski 
 [15] confirmed this hypothesis in their experiments in 1957. Since 
1943 L.H. has developed brownish macules resembling pityriasis 
versicolor on her lower legs ( fig. 7 )  [14] . Since 1975 several actinic 
keratoses, spinocellular carcinomas and basal cell carcinomas 
have been detected in sun-exposed areas, mainly in the face and 
on the scalp. The treatment included cryosurgery, surgery, photo-
dynamic therapy, CO 2 laser, topic 5-fluorouracil and imiquimod 
( fig. 8 ,  9 ). According to our experience, imiquimod cream is the 
best option for actinic keratosis in patients with EV. This treat-
ment has been reported in a recent publication  [16] . The favour-
able activity of imiquimod is probably due to its antiviral activity 
and suggests a viral genesis of the lesions.
 In 2009 we detected HPV-5 in a spinocellular carcinoma. Sec-
tions of the specimens were used for HE staining and DNA prep-
aration. Three consecutive 10-  m paraffin sections from each 
specimen were used for DNA extraction. After deparaffinisation, 
all tissues were subjected to proteinase K digestion in lysis buffer 
(50 m M Tris-HCl, pH 8.5, 1 m M EDTA, 0.5% Tween 20) at 53   °   C 
overnight. DNA was purified using the QIAamp DNA Mini Kit 
(Qiagen, Hilden, Germany) and was directly used for PCR. DNA 
quality was checked by amplification of the   -globin gene se-
quence using the GH20 (5  -GAAGAGCCAAGGACAGGTAC-3  ) 
and PC04 (5  -CAACTTCATCCACGTTCACC-3  ) primer sets 
 [17] . Amplifiable DNA was recovered from all tissue samples. For 
HPV detection we used 4 different protocols as described else-
where: (1) a nested PCR with the outer primer set MY09/MY11 and 
the internal nested primer set GP1/GP2  [17] , (2) a nested PCR with 
the same outer primer pair MY09/MY11 and the internal nested 
primer pair GP5/GP6  [18] , (3) a PCR with the L1C1/L1C2-1 primer 
set  [18] , and (4) a nested PCR protocol to preferentially detect
  -HPV types, using the outer primer set CP62/CP69 and the inter-
nal nested primer set CP65/CP68  [19] . PCR was performed with 
genomic DNA, using 40 cycles for each primer set with the Fast-
Start Taq Polymerase (Roche, Basel, Switzerland) in a total volume 
of 50   l. All assays included positive and negative controls. Ge-
nomic DNA from an HPV-5-containing wart was used as a positive 
control. Water instead of DNA template and normal skin templates 
were used for negative PCR controls. In particular, DNA and PCR 
mixtures were prepared and stored in separate rooms, and positive 
controls were always separated from the test samples and reagents. 
The PCR products were detected by ethidium bromide staining 
after electrophoretic migration through 1.5% agarose gels.
 Amplified HPV PCR products were purified prior to sequenc-
ing, using a High Pure PCR Product Purification Kit (Roche)
according to the manufacturer’s protocol. PCR products were 
submitted to automated sequencing in a Roche FLX genome se-
quencer (Microsynth, Balgach, Switzerland). The resulting DNA 
sequences were aligned against the reference sequences from the 
National Center for Biotechnology Information (NCBI) Entrez 
Nucleotide database using the NCBI BLAST programme. The 
Nucleotide BLAST database was searched to determine the degree 
of homology to known HPV subtypes.
 The EV genes were examined as follows. Genomic DNA of 
L.H. was extracted from peripheral blood lymphocytes after hav-
ing obtained informed consent according to the guidelines of the 
Ethical Committee of Basel. PCR amplification (Qiagen, Valen-
cia, Calif., USA) was performed by means of primers covering the 
entire coding sequence of the  EVER1/TMC6 and  EVER2/TMC8 
genes as well as flanking intronic regions, using sequence infor-
mation as described earlier  [6] . Additional sequence information 
on primers and gene maps was kindly provided by Gerard Orth 
and Michel Favre (Department of Virology, Institute Pasteur, Par-
is, France). Purified PCR products were subjected (QIAquick Gel 
Extraction Kit; Qiagen) to bidirectional sequencing using the
BigDye Terminator Kit (version 3.1) and ABI Prism 377 sequenc-
er (PE Applied Biosystems, Foster City, Calif., USA).
 The obtained results were subjected to computer-assisted 
alignment (BLAST NCBI) utilising sequence information depos-
ited in NCBI GenBank. By using these genetic analyses, a truncat-
ing loss-of-function mutation in the  EVER1/TMC6 or  EVER2/
TMC8 gene could not be detected in the patient. The SNP 
rs7208422 revealed a homozygous mutated genotype in exon 8 of 
the  EVER2/TMC8 gene (c.917A  ]  T) leading to an amino acid 
change (p.N306I), which may be a risk factor for susceptibility to 
  -HPV infection and carcinogenesis  [20, 21] . A further SNP 
(rs2748427) in  EVER1/TMC6 showed a heterozygous mutation 
(c.373T   ]  C; p.W125R). From patient K.T., genomic DNA was 
isolated from paraffin-embedded tissue by using the QIAamp 
DNA Mini Kit (Qiagen) according to the manufacturer’s instruc-
tions for fixed tissues. PCR amplification (Qiagen) was per-
formed, using primers covering the SNP rs7208422 (forward: 5  -
ccgtcgcttccagctgat-3  ; reverse: 5  -acttggtagcccagaagatgg-3  ). Pu-
rified PCR products (NucleoSpin Extract II; Macherey-Nagel, 
Düren, Germany) were subjected to the bidirectional sequencing, 
using the BigDye Terminator Kit (version 1.1) and ABI Prism 377 
sequencer (PE Applied Biosystems) ( fig. 10 ). In patient K.T., the 
same homozygous genotype as in patient L.H. was found.
 Discussion 
 Infections with HPV frequently were not recognised 
and are often clinically unapparent or result in warty le-
sions like verrucae vulgares or condylomas. In the genital 
area, depending on sexual behaviour, everybody can get 
oncogenic   -HPV genotypes (e.g. HPV-16 or HPV-18), po-
tentially leading to the evolution of carcinoma in situ or 
carcinoma of the cervix (or cervical intraepithelial neopla-
sia) or carcinoma of the penis (or prostatic intraepithelial 
neoplasia). In contrast EV patients are genetically predis-
posed to get oncogenic   -HPV by an abnormal susceptibil-
ity to these viruses, mainly to type 5, but also to types 8, 4, 
17, 20 and 47  [2] . Half of these patients develop skin cancer 
 [22] . In the unaffected population   -HPV do not lead to a 
clinical manifestation because of an intact barrier against 
the HPV of the beta genus. The susceptibility of EV pa-
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tients is genetically determined and inherited by an auto-
somal recessive trait  [5] . Two responsible genes on chromo-
some 17q25 have been identified, which were called  EVER1/
TMC6 and  EVER2/TMC8  [6] . Several loss-of-function mu-
tations have been identified in both genes. These mutations 
resulted from different mechanisms like nonsense muta-
tions, deletion of exons, splice site mutations or single-nu-
cleotide mutations  [2, 6, 16, 21, 23–28] . No  EVER1/TMC6 
or  EVER2/TMC8 mutations have been detected in 25% of 
EV patients (including familial cases), revealing the het-
erogeneity of the disease  [2, 29] . In a case-control study, 
Patel et al.  [20] found that the A-to-T base substitution at 
the position c.917 in exon 8 of  EVER2/TMC8, a SNP 
(rs7208422), resulting in an amino acid exchange of as-
paragine for isoleucine, probably has a role in skin carci-
nogenesis in the general population. The TT homozygous 
genotype (p.N306I) is assumedly a risk factor for suscepti-
bility to   -HPV infection and non-melanoma skin cancer 
 [20, 21] . This homozygous genotype is found in approxi-
mately 27% of the European population  [30] . We found a 
further SNP (rs2748427) in  EVER1/TMC6 showing a het-
erozygous mutation (c.373T   ]   C; p.W125R). It remains 
highly speculative whether the heterozygote polymor-
phism rs2748427 in  EVER1/TMC6  in a patient addition-
ally displaying the homozygote polymorphism rs7208422 
in  EVER2/TMC8 induces a more defective formation of the 
whole EVER/ZnT-1 complex than the homozygote poly-
morphism rs7208422 in  EVER2/TMC8 alone. Probably 
there is another disease-defining mutation on chromo-
some 2 which we have not yet examined. Nevertheless our 
findings add some support to the hypothesis that these 
polymorphisms could somehow influence the susceptibil-
ity to   -HPV and their oncogenic potential. Transcripts of 
 EVER1/TMC6  and  EVER2/TMC8 were detected in lym-
phoblastoid cells and in normal skin  [6] , and recently pub-
lished data suggest that  EVER1/TMC6 and  EVER2/TMC8 
are highly expressed in various types of haematopoietic 
cells  [31] . TMC genes encode integral membrane proteins 
that localise to the endoplasmic reticulum and are predict-
ed to form transmembrane channels. The exact function 
of these proteins is still unclear, but it is assumed that they 
belong to a new group of channels or ion transporters and 
could be involved in signal transduction  [7, 8] .  EVER1/
TMC6 and  EVER2/TMC8 act as modifiers of zinc trans-
porter ZnT-1. Potentially, EVER proteins mediate the pro-
tection against oncogenic HPV via regulation of cellular 
zinc balance  [9, 10] . A mutation in the EVER1 or EVER2 
gene might block the formation of the EVER/ZnT-1 com-
plex, which would allow the expression of transcription 
factors (e.g. AP-1), thus promoting viral replication  [32] .
 Conclusion 
 In EV patients there is a strong association between 
  -HPV infection and non-melanoma skin cancer. This 
predisposition is genetically determined by mutations of 
the 2 genes  EVER1/TMC6 and  EVER2/TMC8. However, 
only in 75% of EV patients, an  EVER mutation has been 
found. This suggests other genes are involved. A second 
EV susceptibility locus on chromosome 2p21–p24 by au-
tosomal recessive inheritance is assumed  [5] . X-linked re-
cessive inheritance  [33] and autosomal dominant trans-
mission have been reported  [34] . Further gene identifica-
tion associated with EV could reveal new insights into 
host defence against HPV and, thereafter, HPV-associat-
ed carcinogenesis. Besides UV light there are other pos-
sible additional risk factors such as immunosuppression, 
HIV infection, lymphoma and graft-versus-host disease 
 [21, 35–39] . Probably these states of immunosuppression 
and the UV irradiation exhibit a second hit for the devel-
opment of skin carcinomas in patients with the  EVER 
mutation. Recently, EV-like syndrome has been described 
in patients with impaired cell-mediated immunity, and 
the term of ‘acquired EV’ has been introduced  [40] .
 In our patients we demonstrated the TT genotype 
(SNP rs7208422) in the  EVER2/TMC8  gene as well as a 
further heterozygous SNP (rs2748427) in  EVER1/TMC6, 
which very likely makes patients vulnerable to oncogenic 
  -HPV such as HPV-5 and HPV-8. There is no absolute 
proof that these polymorphisms cause the clinical signs 
of EV in our 2 patients. However it supports a possible 
role of rs7208422 in skin carcinogenesis. The mutated 
gene which is responsible for the disease in our patients 
remains to be definitively identified. It is probably located 
on chromosome 2, which still has to be analysed.
 We have followed until today one of the first patients 
described with EV, diagnosed by Wilhelm Lutz in Basel 
already in 1930. L.H. is probably the oldest living subject 
with this disease. This is a historically and scientifically 
interesting subject. The story began in Basel with the ob-
servation of 4 patients, having led to a helpful explanation 
of skin carcinogenesis  [32] .
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